EZRA INNOVATIONS LLC

Executive Summary EZRA has a unique opportunity to develop Generic versions of branded drugs which face limited generic competition due to difficulties in formulation. EZRAs core business revolves around a unique, mathematicallybased drug delivery technology called the Asymmetrically Controlled Tablet (ACT). This technology allows EZRA to develop a number of high barrier-to-entry, generic versions of extended release (once-daily) drugs. Pharmaceutical companies utilize drug delivery technology to preserve their brand drug franchises long past the 20 years of chemical patent protection. They do this by introducing a new improved drug formulation. The improved formulation may have gone from a three-times-daily dose, to a once-daily dose. For example, the ADHD drugs Concerta, Focalin, and the Central Nervous System drug Wellbutrin XL were given in multidose formats but are now delivered in once-daily formulations utilizing the brands own unique drug delivery technology. This accomplishes the following for the brand from a business perspective: The improved once-daily version of the drug franchise is intentionally difficult to engineer, limiting generic competition and extending the brand life and pricing structure years beyond the initial chemical patent. For example Wellbutrin was moved to Wellbutrin XL after its first number of years of the patent was expired. EZRA can compete against the pharmaceuticals expensive brand in generic form because of its unique drug delivery technology assessing a large pre-built market. EZRAs drug delivery technology is flexible in design so that it can be engineered to control and manipulate the release of the targeted chemical compound over a 24-hour period. The design of the intended EZRA generic drug does not infringe on the branded pharmaceuticals patent, and/or drug delivery patent, and concurrently satisfies the FDA requirements for generic equivalence. Therefore, EZRAs technology has the capacity to move around complicated delivery systems and engineered formulations as the generic alternative. Through this process, EZRA, working with a generic pharmaceutical distribution partner, can become a leading alternative against the innovators branded drug. One specific example that highlights the EZRA model is Anchen Pharmaceuticals. Anchen created a generic competitor to the once-daily version of GSKs Wellbutrin XL without infringing on GSKs patents. Anchen then partnered with the largest generic company in the world, TEVA Pharmaceuticals, to assist in commercializing the drug. Within the first year of generic sales, Anchen/TEVA captured 70% of the Wellbutrin XL franchise representing $650M of the $1.1B Wellbutrin XL produced in sales. EZRA has several opportunities to develop high barrier-to-entry generic drug formulations utilizing its drug delivery technology, the Asymmetrical Coated Tablet (ACT). Each target drug franchise currently sells in excess of $600M USD annually. EZRA plans to develop each drug with a modest capital raise and/or partnering with a large international generic company(s). This is the same model as that for Anchen discussed above. By partnering, EZRA can compete in a very capital intensive industry. In addition, EZRA transfers much of the financial and legal risk to a competent and established market partner with strong distribution capabilities. The EZRA technology is a platform with which many generic drugs will be developed. It can also be used for branded drugs for which the delivery profile is difficult, in addition to being used with newly formulated drug compounds.

CONFIDENTIAL 1

EZRA INNOVATIONS LLC

FDA Regulatory Guidance EZRA follows the generic Abbreviated New Drug Application process. This is a short, well defined process outlined by the FDA which allows for generic drug approval to the brand named drug. The Pioneer brand drug has already completed the difficult clinical trial which may have required 7.5 years time and inordinate amounts of money. EZRA simply has to conduct a blood level study comparing the release of EZRAs drug in the body to the brand (36 patients). For this reason, EZRA can conduct a number of trials for generic drug approval supporting a valuable suite of products. Drug Development Timeline: Brand versus EZRA Generic Brand Clinical Trial (New Drug Application) Phase 1 1-2 Years EZRA-Generic Trial (Abbreviated New Drug Application) Manufacturing and Equivalence Testing (Blood Level Study) +18 Months 15-24 months EZRA relies upon the Food and Drug Administrations (FDA), expedited approval process referred to as the Abbreviated New Drug Application. Approximate EZRA development and FDA approval time is 39 months versus the Brands New Drug Application of 7.5 years. Capital and Use of Proceeds EZRA is currently raising $6.5M USD to complete generic clinical development of its first high-value drug target. EZRA will fund the development of the second drug through existing funds, and funds from Milestone payments from strategic partners. EZRA will initiate each new generic drug development cycle on a yearly basis therefore stacking its product pipeline. Within 3-4 Years, EZRA will have built a generic drug pipeline in excess of $150M dollars, proven its unique drug delivery technology, and ideally achieved its target of possible exit valuation in excess of $250M. Phase II +2 Years FDA Approval Time 39 Months Phase III and Total Time FDA Approval Time +3.5 years 7.5 years

CONFIDENTIAL 2

EZRA INNOVATIONS LLC

EZRA Drug Market Strategies The initial EZRA strategy allows EZRA to enter into an agreement with a highly experienced and capable generic partner. Once funds accrue from Drug 1 Revenues, EZRA can initiate the second drug clinical trials where EZRA develops a drug and again partners with a distribution partner. Additionally, new drug developers have expressed interest in EZRAs unique drug delivery technology for their own drug programs. EZRA could initiate a go-tomarket strategy but anticipates company exits prior to any go-to-market drugs are launched. Strategic Partners/Competitors 1. Within the generic market, there are three (3) types of competitors that can also be classified as potential partners for EZRA. A partnership can be formed with any of the following classes of competitors, for example the first class would be illustrative of the Anchen-Teva partnership. Large, well-established generic companies such as, Teva, Watson, and Sandoz; or, 2. Mid-size generic companies such as, Par Laboratories, Impaxx Labs, Prasco; or, 3. Large pharmaceutical companies looking for generic opportunities such as, Pfizer and many others. EZRA Revenue Projections: Drug 1 Revenue: Milestone payments expected year two and three, with royalties beginning year 4 on both drugs. In this model EZRA partners with larger drug company as noted under Strategic partners/Competitors title of this document.

Year 1
Drug 1 Revenue Drug 2 Revenue Total Drug Revenues Interest Incom e UAMS Royalty Developer Royalty Gross Profit

Year 2 3,000,000 3,000,000 44,434 150,000 2,894,434

Year 3

Year 4 60,000,000 25,000,000 85,000,000 23,684 4,250,000 80,773,684

Year 5 80,000,000 175,000,000 255,000,000 1,103,779 12,750,000 20,000,000 223,353,779

Year 6 80,000,000 200,000,000 280,000,000 2,925,164 14,000,000 20,000,000 248,925,164

81,938 0 81,938

3,000,000 3,000,000 70,735 150,000 2,920,735

Drug Target Overviews Drug 1 currently sells in excess of $600M in annual revenue. The active chemical ingredient (API) is difficult to deliver throughout the Gastro Intestinal tract. The drug delivery technology utilized by the innovator for sustained release is patented, and is also specialized to that particular API, therefore keeping high-barriers to entry for generic competition. EZRA is able to develop this drug in its own unique ACT Drug Delivery Technology. EZRA does not infringe on the innovators drug delivery system. Drug 2 currently sells in excess of $900M in annual revenue. The active chemical ingredient (API) is difficult to deliver throughout the Gastro Intestinal tract. The drug delivery technology utilized by the innovator for sustained release is patented, and is also specialized to that particular API, therefore keeping high-barriers to entry for generic competition. EZRA is able to develop this drug in its own unique ACT Drug Delivery Technology. EZRA does not infringe on the innovators drug delivery system.

CONFIDENTIAL 3

EZRA INNOVATIONS LLC

As Cash Flow Allows for Development Drug 3 currently sells $1.1B in annual revenue. This formulation was once given twice-daily and now has a oncedaily dosing regimen. The old molecule has gone off patent, and a new patent has been written around the formulation of the drugs release. EZRA, with its ACT Technology, can satisfy the FDA requirements for generic approval, and not infringe on the formulation patent which currently exists. Freedom-to-Operate opinions have been provided to EZRA from reputable outside counsel. Drug 4 currently sells over $1Billion in annual revenue. Due to current problems in formulation, the active chemical ingredient (API) is extremely sensitive to light, heat, moisture, and humidity, The shelf life of the drug target is currently at 12-15 months creating a problem for the supply chain where a 2-3 year shelf life is expected. EZRA believes we can increase the shelf life by greater than six months in the ACT delivery system. EZRA has two advantages working with this drug: First, EZRA is working with the original inventor and scientist of the innovator drug and Second, EZRAs specialized delivery system can protect the active molecule against the degrading elements.

Generic Drug Pricing Model Below is a hypothetical example of direct to consumer drug pricing and market share as generic competitors enter the marketplace. The brand controls 100% of the market for many years leaving hurdles in place, such as difficulties in formulations or key patents. A generic company cannot enter the market until: a) the patent expires or the patent is invalidated, b) the generic is non-infringing to the brands patents, or c) the formulations are duplicated in a completely different delivery system. Provided one of the avenues is taken from the above options, generic competitors put downward pressure on prices and significantly erode market share based solely on a low price strategy. Each subsequent generic introduced, will correct to the lower price with those previous introduced. Typically, the brand does not follow and keeps their premium pricing in place.

Brand Price Market Share Year 1 Year 2-5 Year 5-10 $150 100% 20% 20% 10%

First Generic $120 0 80% 50% 30%

Second Generic $90

Third Generic $70

Fourth Generic $35

30% 20% 20% 20%

CONFIDENTIAL 4

EZRA INNOVATIONS LLC

EZRAs Unique Technology EZRAs drug delivery technology allows EZRA to target difficult formulations. Not all drug delivery technologies work in the same fashion. For example, in the graph below, several independent technologies have been developed specifically for each franchise. Each franchise has its own particular technological hurdles to deliver the active chemical compound at the right time and location in the body. EZRAs single technology can replicating all 3 drug franchises, and mimic 90% of the sustained release, once-daily drugs in the market. In total, these 3 franchises sell $2B a year. The Outer Core is a water-insoluble shell, with a top layer, or cap which may, or may not contain drug chemical The core with in the shell is a layered matrix of active drug. This matrix provides sustained release properties. Utilizing the mathematics of the constant exposed surface area of the matrix, manipulation of FDA approved Polymers, and mathematical asymmetrical design properties, the ACT system is able to control and manipulate release rates of the drug, and location of release in the body.

Competitive Advantages of the ACT Technology EZRA matches one or more advantages to the brand technology, and/or other competitors in choosing its drug targets. To be approved as an FDA generic substitute, EZRA must demonstrate bioequivalence with the brand drug. Being able to replicate across a spectrum of drug franchises without infringement to the formulation or the brands technology is competitive advantage of the ACT platform; allowing EZRA access to large markets. Being able to provide higher milligram strength dose-loads in a sustained release fashion is a distinct competitive advantage. Price of manufacturer on a per pill basis is substantially less than other drug delivery technologies (note examples in above graph). Being able to control and manipulate the release profiles of several sustained release drug delivery technologies utilizing mathematics and geometry, where other technologies are designed from a biological perspective specifically with the delivery of the brands active ingredient in mind.

The following illustrates a single design ACT tablet:

Cross-Sectional

CONFIDENTIAL 5

EZRA INNOVATIONS LLC

Top Inner Core Outer Coating

Below is an example of EZRAs ACT Technology compared to conventional Tablet-in-Tablet design.
EZRA ACT Technology Compared to Tablet-in-Tablet

asymmetrical

symmetrical

water-insoluble polymer

water-soluble polymer

Below is an example of several Drug Designs in the ACT platform:

CONFIDENTIAL 6

EZRA INNOVATIONS LLC

As demonstrated below, the EZRA simulations track the brand drugs release, demonstrate bioequlivancy, and fall within the FDA parameters for generic approval. This in-vitro testing needs to be replicated in human clinical trials to satisfy FDA ANDA (Abbreviated New Drug Application) guidelines. Please note that the ANDA guidelines do not require a demonstration of either drug safety or efficacy, EZRA needs to only demonstrate bio equivalence.

Operations Summary EZRA, in an effort to control both startup costs and maintain complex industry levels of excellence and compliance, will initially outsource testing, compliance, and marketing functions. By implementing an effective outsource strategy, EZRA is capitalizing on top industry experts and reducing select industry risks. EZRA recreates the expertise of a Large Pharmaceutical company in a lean and nimble small organization. EZRA Core drug development experts have developed over 200 drugs from start to finish. The advisory board careers span years at Merck, Johnson and Johnson, Teva, Watson and Perrigo company.

CONFIDENTIAL 7

EZRA INNOVATIONS LLC

Clinical Manufacturing EZRA will outsource all clinical batch manufacturing to a designated Contract Manufacturing Organization (CMO). The CMO that has been selected has an outstanding reputation with the Food and Drug Administration and has 5 of the top 10 pharmaceutical companies as clients. ACT can be commercially manufactured by a three-step or one-step processes at their location. Clinical Trials The drugs targeted by EZRA have already been FDA approved for their original indications (efficacy and safety). Because the underlying drug compounds have already been approved by the FDA, EZRA will be filing a generic ANDA which requires only a truncated approval process, of which a Pivotal Fasting Study 36 subjects without food, and a pivotal fed with food, 24 subjects in order to demonstrate bioequivalence. The human clinical trials would cover a period of approximately 12-15 months. EZRA has identified a leading Contract Research Organization.

Clinical Timeline - approximate The following timeline illustrates the development process and estimated market entry for EZRAs initial partnered drug product.

Clinical Manufacturing

Pilot Study 9 Patients 3-Way Crossover Could Partner

26-36 Fasted/ Fed Clinical Trial Could Partner Month 12-15

Submission of Application to FDA (Partner) Milestone Payment Month 15-17

FDA Approval Time Milestone Payment Month 39 34-

Market Launch

Royalty To EZRA Month 39

Month 0

Month 9-11

Note: Deal value increases as objectives are met.

Brand and Generic Market Analysis The #1 selling brand drug in the United States is Lipitor, generating $5.8 billion in sales annually, followed by th Nexium with over $4.7 billion in sales (2008). The 200 ranked brand drug in sales revenue is Xopenex HFA, coming in at $151 million in revenue. Brand drugs finishing outside the top 200 had additional combined sales of nearly $26 billion. The generic drug industry alone will generate an estimated $40 billion in sales by 2010 (US th only). The #1 selling generic drug is Hydrocodone which generated $1.7 billion, while the 200 selling generic had $46 million in sales. Those generics outside the top 200 sold an additional $6.7 billion (2008). Of note, nearly $13 billion of brand pharmaceutical patents expired in 2007 alone. A single drug, when taking EZRA business model into consideration, could generate hundreds of millions in revenue for the company. For

CONFIDENTIAL 8

EZRA INNOVATIONS LLC

example, 10% of the 1.2B generic Toprol market would position EZRA as a +$100M in revenue company. Over the next five years, sales of generic drugs are expected to grow by 10-12% per year (Data Monitor Report 2009), outselling overall pharmaceuticals demand which is projected to increase at 7-8% per year. EZRA Patent Estate and Strategy EZRA has licensed the rights to the Asymmetrical Coated Tablet, drug delivery technology, from the University of Arkansas for Medical Sciences. Additional international patents and manufacturing patents have been filed for the ACT technology. Provisional patent was filed 7-08-05 and published 1-11-07. EZRA is at first office action with the USPTO.

Sources and Uses of Cash

Year 1 Source of Cash Investment Interest Income Drug 1 Revenue Drug 2 Revenue 6,500,000 81,938 0 0 6,581,938

Year 2

Year 3

Year 4

Year 5

Year 6

44,434 3,000,000 0 3,044,434

70,735 0 3,000,000 3,070,735

23,684 60,000,000 25,000,000 85,023,684

1,103,779 80,000,000 175,000,000 256,103,779

2,925,164 80,000,000 200,000,000 282,925,164

Use of Proceeds Repurchase of Member Interest Accounts Payable Royalties Paid Operations Clinical Development Fixed Assets Member Distributions

(200,000) (60,000) 0 (870,000) (940,000) (5,000) 0 (2,075,000) 4,506,938

(150,000) (1,274,300) (1,655,000) (10,000) 0 (3,089,300) (44,866)

(150,000) (1,360,500) (715,000) (30,000) (422,618) (2,678,118) 392,618

(4,250,000) (2,318,000) (940,000) (40,000) (38,757,842) (46,305,842) 38,717,842

(32,750,000) (34,000,000) (2,674,000) (4,391,050) (1,805,000) (1,805,000) (85,000) (60,000) (109,437,390) (121,364,557) (146,751,390) (161,620,607) 109,352,390 121,304,557

Increase/(Decrease) Cash

Cumulative Cash Balance

4,506,938

4,462,072

4,854,690

43,572,532

152,924,921

274,229,478

Net Present Value of 6 year Cash Flow

CONFIDENTIAL 9

EZRA INNOVATIONS LLC

Assuming a 15% Annual Discount Factor $133,091,127

Management Dr. Cherng-ju Kim, Ph.D. Inventor and Drug Delivery Consultant He is a Professor in the Department of Pharmaceutical Sciences at the College of Pharmacy, University of Arkansas for Medical Sciences (UAMS). Dr. Kim holds a Ph.D. in Chemical Engineering (1984) from McMaster University, Hamilton, Ontario, Canada with a Major in Polymer Reaction Engineering. A Masters in Engineering (Environmental) (1979) from Environmental Science and Engineering Department at Manhattan College, Riverside, N.Y. and a Bachelors in Engineering in Chemical Engineering (1974) from Korea University, Seoul, Korea. In 1986, he founded Khimm Chemical Co., Toronto, Ontario, Canada to develop and market reverse osmosis membranes for home drinking water systems. He later sold his interest in 1988. From 1984 to 1986 Dr. Kim was a research Scientist, Membrane Research and Development with Zenon Environmental, Inc., Burlington, Ontario, Canada where he worked on developing synthetic ultra-filtration membrane for treating food processing wastewater. Dr. Kim currently holds six patents, and has written three books and 71 academic papers, all addressing pharmaceutics. Michael Geranen Chairman / CEO Founding member of EZRA Innovations LLC, subsequently Michael was with CAM-Global, a firm dedicated to the success of young Health Care and Life Science based companies. In his capacity as an investment banker and consultant, Michael has assisted many companies in the development and execution of their business models through various measures of Corporate Development; including business planning, competitive intelligence, market research, sales force development and alliance management. Subsequently two products Michael has worked on are being marketed nationwide under the brands of Quigley, Inc. and SinoFresh HealthCare. Michael is also one of two founding members of Assura Pharmaceuticals, a CAM-Global portfolio company dedicated to providing safe and effective medicines to the general public. He has worked on many projects with companies such as Pfizer, Aventis, J&J and other organizations. Michael attended Lutheran College, Finlandia University

CONFIDENTIAL 10

EZRA INNOVATIONS LLC

with a major in Computer Engineering and is a Veteran of the Elite U.S. Army Ranger Regiment serving with distinction. Dr. Joe Fix, Ph.D. Chief Operations Officer A world renowned drug delivery and product development expert with over 30 years experience spanning discovery support through product launch with numerous drug approvals under his belt. Previous management positions: www.pharma-fix.com. President & COO, CyDex, Inc Exec VP & COO, Elan NanoSystems President and CTO, Yamanouchi Pharma Assoc Dir, Biopharmaceutics, Alza Assoc Dir, Biopharmaceutics, Merck Terrence L. Shockley President (Consulting) Mr. Shockley has over 28 years experience in the pharmaceutical industry, the last 18 spent at the executive level. Mr. Shockley began his pharmaceutical career with Berlex Laboratories, where he spent 5 years gaining insight into big pharma organization, infrastructure, and sales and marketing techniques. At Berlex he held positions in sales, training, marketing, and advertising. After leaving Berlex, Mr. Shockley served 15 years with Ion Laboratories, Inc. holding positions in sales training, management, and as Vice President of Sales and Marketing. In 1994, Mr. Shockley left Ion Laboratories to accept the position of Vice President with Capellon Pharmaceuticals, Inc., a start-up specialty pharmaceutical company focused on respiratory and gastroenterology products. He was asked to join a dental specialty pharmaceutical company in 2005 and led all start-up operations for the firm. Mr. Shockley holds two Masters degrees (Chemistry and Biology) from Angelo State University Brett Mathews, CPA Consulting CFO Serves in a consulting capacity as Ezra's Chief Financial Officer. He is a principal in the accounting firm Matthews,Cutrer & Lindsay, PA, located in Ridgeland, Ms. He is responsible for accounting oversight, strategic financial and tax planning. Brett earned his Bachelor of Science in Accounting in 1975 from Mississippi State University. He is a licensed CPA in the State of Mississippi. His professional memberships include the American Institute of Certified Public Accountants, the Mississippi Society of Certified Public Accountants and the MSCPA's Peer Review Committee. Dr. Shirish Shah, Ph.D. Consultant, Regulatory Affairs Dr. Shah received his Ph.D. in Pharmaceutics from the University of Iowa, Dr. Shah has over 8 patents granted and personally developed over 200 Generic Drugs while working for Watson Pharmaceuticals, Teva and Perriogo company. Dr. Shahs notable responsibilities at Watson Pharmaceuticals include management of three groups, of approx 30 employees (including 6 Ph.D.), responsible for formulation development, scale-up and analytical development of high barrier Generic and Brand solid dosage forms. Dotted line management responsibilities for project management, regulatory affairs and biopharmaceutics. Directed the new product development program., Filed six ANDAs, one of which was a transmucosal dosage form of pain medication with complex design and technology that was developed and filed on a very short timeline. Expedited the manufacture of a proprietary Controlled Release pain product for Phase II Clinical Studies. Dr. Shahs notable responsibilities at Perrigo Company include leading a group of up to 18 scientists and technicians to develop 30-35 new Generic products per year, Dr. Shah successfully developed many first to market generics, including common household names such as Tylenol extra strength. Dr. Shah served as

CONFIDENTIAL 11

EZRA INNOVATIONS LLC

technical / scientific key team member of the Pharmaceutical Business Development group responsible for the acquisition, licensing, contract development and manufacture of special technology based products. Robert H. Lake, Executive Vice President, (Consulting) Sales & Marketing / Director Rob graduated from the University of Mississippi in 1981 with a Bachelor of Arts degree in Biology. He began his pharmaceutical career in 1984 with Wyeth Laboratories where he served as a Hospital Representative. Rob then joined Fisons Corporation as a National Accounts Manager, working in areas such as National Account coverage, Marketing, Sales, Finance, Customer Service, and Distribution. He has held executive level positions with Capellon Pharmaceuticals, Primus Pharmaceuticals and most recently with Adamis Laboratories. Rob has over 25 years experience in launching Rx products and distributing those products to wholesale and pharmacy retail outlets. He is a member of several important pharmaceutical organizations, which includes the National Association of Chain Drug Stores, Healthcare Distributors Marketing Association, and the Food and Marketing Institute. He was a nominee for the prestigious 1994 Diana Award for outstanding trade practices in the pharmaceutical industry. . Dr. Tery Baskin, Pharm D - Advisory Board Member Tery Baskin currently serves as President and CEO of RxResults, a private company that provides and evidence based medicine approach to managing a pharmacy benefit. RxResults has a strategic relationship with a UAMS college of pharmacy and provides objective analytics and recommendations to employers. Health plans and Medicaid programs. Tery Baskin has served as the Chief Operating Officer and Chief Marketing Officer for NMHC, a publicly traded PBM headquartered in Port Washington, NY. His responsibilities as COO included the performance of Clinical Services, Operations, Account Services and Operational Services. As CMO he was responsible for managing the organic growth of the company across all four divisions: PBM, Mail, Specialty and Health Information Management. Tery Baskin previously served as President of PAI for twelve years, a company acquired by NMHC in July 2000. Tery has owned three community pharmacies and also worked on staff at a tertiary care hospital. This patient care experience has been valuable in trying to save money for clients without sacrificing the quality of care their employees receive. Tery has been very active in pharmacy associations on both a state and national level, serving as President of the Arkansas Pharmacists Association and also on the Board of Trustees of the American Pharmacists Association. He also served on the APhA Foundation Board of directors for six years including one as President. He has made numerous presentations across the U.S. and abroad on the subject of The Pharmacist Role in Managed Care and the Future of Pharmacy. His presentations include the U.S. Senate Committee on Aging and Hillary Clintons Task Force on Health Care Reform. Dr. James K. Hendren, Ph.D. - Board Member - Managing Advisor James K. Hendren, Ph.D., has been a leader in raising the awareness of the importance of technology and knowledge job development in Arkansas economic growth strategy since the mid - 1980s. He received his doctorate in physics from the University of Arkansas in 1972, providing a foundation for his successful career in sophisticated software development in both the defense and banking industries. From 1972-1977, he worked for the in the US Army Antiballistic Missile Defense agencies and for Science Applications Inc. (now SAIC). From 1980-1998, James was President, then Chairman of Arkansas Systems, Inc. (ARKSYS), one of Arkansas early high-tech companies. While growing that company from a small, home -grown company to an internationally known corporation, he served on the Arkansas Science & Technology Authority board of directors and helped organize the non-profit Association of Knowledge-based Companies of Arkansas. Appointed in 1999 by the Governor to serve on the Arkansas Economic Development Commission, he has continued his advocacy for a statewide technology strategy and most recently chaired the ADEDs State Taskforce on Advancing Knowledge Based Jobs. He was a member of the Governors Blue Ribbon Commission on Higher Educa tion. He is a founding member and actively involved with Accelerate Arkansas to improve the average wage in Arkansas through technology serving on its executive committee and its strategic planning committee. He also is involved as an investor / advisor to over fifteen start-up technology companies. He is actively involved in a number of nonprofit organizations including the Quapaw Area Council, Boy Scouts of America where he has served in many

CONFIDENTIAL 12

EZRA INNOVATIONS LLC

positions from Scoutmaster to Council President. Dr. Michael Douglas, Ph.D. - Advisory Board Member Dr. Douglas currently serves as the Director of the UAMS BioVentures a biomedical technology licensing and life science technology incubator of the University of Arkansas Medical Sciences. He also serves as Professor of Biochemistry and Molecular Biology in the UAMS graduate school and College of Medicine. Prior to 2006 he served in various university, public and private organizations in St Louis, Missouri. In the university he was Associate Vice Chancellor and Director of the Office of Technology Management at Washington University. In the private sector he has served as Chief Executive and Scientific Officer of Novactyl, Inc., a clinical stage pharmaceutical development company. From 1994 to 1998 he was the Chief Executive Officer and Chairman of the Board of Sigma Diagnostics, a multinational clinical diagnostics company. Prior this he held various university faculty positions in North Carolina and Texas. He served as Professor and Chairman of Biochemistry and Biophysics and in the Curriculum in Genetics and Molecular Biology and Biotechnology at the University of North Carolina Medical School, Chapel Hill, North Carolina from 1989 to 1994. Prior to this he advanced through the academic faculty ranks at the University of Texas Medical Schools in San Antonio and Dallas. Dr Douglas continues his research interests and has authored numerous peer reviewed scientific articles and is an elected member of different scientific and professional societies. He maintains active positions on various civic, corporate, academic and scientific advisory boards in the Midwest and abroad. He received his BS degree in Chemistry and Biology from Southwestern University and his PhD from Saint Louis University. He is decorated veteran of the Vietnam conflict. He is married to Joanne and has three grown children, Hannah, Peter and Sarah.

This overview is for informational purposes and is not an offer to sell or a solicitation of an offer to buy any securities in EZRA Innovations, LLC, or any of its subsidiaries, and may not be relied upon in connection with the purchase or sale of any security.

CONFIDENTIAL 13

EZRA INNOVATIONS LLC

CONFIDENTIAL 14